Published in Cancer Weekly, February 8th, 2005
According to published research from Japan, "immunosuppressive therapy for organ transplantation is essential for controlling rejection. When liver transplantation is performed as a therapy for hepatocellular carcinoma (HCC), recurrent HCC is one of the most fatal complications. In this study, we show that intratumoral murine interleukin-12 (mIL-12) gene therapy has the potential to be an effective treatment for malignancies under immunosuppression."
"C3H mice (H-2kappa ), injected with FK506 (3 mg/kg) i.p., were s.c. implanted with 2.5 x 106 MH134 cells...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.